IGF-1 LR3 Testing: Folding, Disulfides and What Mass Can’t Show

Most research peptides can be characterised with a mass spectrum and an HPLC trace. IGF-1 LR3 is where that toolkit stops being enough. At 83 residues with three internal disulfide bonds, it is a small protein, and the defects that matter most are about folding and aggregation rather than composition. This article explains what the name describes, which measurements confirm correct structure and which cannot, and what a cell-culture or QC lab should look for when sourcing Long R3 IGF-1 in volume.

What the “Long” and the “R3” mean

Native IGF-1 is a single chain of 70 residues with three disulfide bridges and an average mass of about 7649 Da. The research analogue modifies it in two places:

• R3: the glutamate at position 3 of the IGF-1 sequence is replaced with arginine.
• Long: a 13-residue extension, Met-Phe-Pro-Ala-Met-Pro-Leu-Ser-Ser-Leu-Phe-Val-Asn, is added to the N-terminus.

The result is 83 residues. In the in-vitro literature these changes are described as sharply reducing binding to IGF-binding proteins while keeping activity at the IGF-1 receptor, which is why the analogue is used as a cell-culture reagent. For QC purposes, the important numbers are the masses.

IGF-1 LR3 mass checks: what they settle

Each disulfide bond forms with the loss of two hydrogen atoms. Three bonds means the folded molecule is about 6 Da lighter than the reduced chain. On a protein of 9.1 kDa, that shift is small but well within reach of a properly calibrated instrument, so an intact mass measurement can confirm that the cysteines are paired rather than free.

The same spectrum answers two other quick questions. A mass near 7649 means unmodified IGF-1 was supplied. A +16 Da satellite points to methionine oxidation, and IGF-1 LR3 has three methionines to oxidise: two in the extension and one in the IGF-1 portion.

Reading the charge envelope

Electrospray spreads a protein this size over many charge states. For a 9111.5 Da molecule, the 7+ ion falls near m/z 1302.6 and the 9+ ion near m/z 1013.4. How far the envelope extends is informative in itself. A compactly folded protein exposes fewer basic sites and tends toward lower charge states; unfolded material picks up more protons and shifts toward higher charges. A distribution skewed to high charge is an early hint of a folding problem.

The blind spot: disulfide scrambling

Six cysteines can be paired into three bonds in 15 different ways. Just one pattern is correct. The other fourteen have exactly the same formula and exactly the same mass.

So a correct 9111.5 Da result proves that three disulfides exist, not that they are the right three. Mispaired isoforms are the defining quality risk for a protein like this, and intact mass cannot see them. Two approaches can:

1. Non-reduced peptide mapping. The protein is digested without breaking the disulfides, and the linked fragments are identified by LC-MS to show which cysteines are bonded to which.
2. High-resolution chromatography. Misfolded isoforms present different surfaces and usually separate by reversed-phase HPLC, even though their masses match. The method must be shown to resolve them for the result to mean much.

Why reversed-phase purity reads differently on a protein

On a short peptide, a reversed-phase area percentage mainly counts species of different composition. On a folded protein, it also counts conformational variants, and whether it does so is a property of the method. A wide main peak, or one with a shoulder, is more likely to reflect isoforms than an unrelated contaminant. A single sharp peak from a method that has never been shown to separate isoforms proves less than it seems to.

Reversed-phase conditions also denature proteins, so non-covalent aggregates can fall apart on the column and never appear. That is why protein documentation usually adds orthogonal methods.

Complementary tests worth asking for

• Size exclusion chromatography under native conditions, to quantify dimers and higher aggregates.
• Reduced and non-reduced SDS-PAGE run side by side, which shows whether disulfides are present and whether any link separate molecules together.
• Peptide mapping, which confirms the sequence and pins any modification to a specific residue.
• Endotoxin, since proteins of this length are made by recombinant expression, typically in bacteria, and endotoxin matters for cell-based work.

Recombinant production also changes the impurity list. Failed-coupling deletions from chemical synthesis are not the concern. Host-cell proteins, residual DNA, truncated expression products and incorrect N-terminal processing are, and they are measured with different methods.

Sourcing and storing it for a cell-culture programme

Labs that use IGF-1 LR3 as a culture reagent often buy enough for months of work, which makes lot control central:

• Request enough of one lot to cover a defined series of experiments, so changes in results are not confounded by a lot change.
• Record the intact mass, SEC aggregate level and endotoxin figure for each lot in the inventory log.
• Keep the lyophilised material cold and dry, and divide working stocks into single-use aliquots to avoid repeated freeze-thaw cycles, which promote aggregation.
• Note the formulation on arrival, since excipients or carrier protein change how the material behaves and how concentration should be calculated.

Bulk Peptides does not currently list IGF-1 LR3. For the peptides we carry, independent HPLC purity testing is standard practice, certificates for some are posted on the certificates of analysis page, and cap and crimp colour identifies which certificate belongs to each vial.

IGF-1 LR3 is discussed here purely as an in-vitro laboratory reagent. Research compounds are not for human or veterinary use in any form.